Toulouse

• Study of Tumor Alterations Responsive to Targeting Receptor Kinases-2 Ended recruitment
  2023-505034-10-00 4 2016-08-01 Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS
• Filling bone erosions: a longitudinal multicentric HR-pQCT study of subcutaneous tocilizumab in rheumatoid arthritis Ended recruitment
  2024-517686-17-01 6 2016-06-30 rheumatoid arthritis
• A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Rheumatoid Arthritis who are on a Stable Dose of Meth … Ended recruitment
  2022-501017-31-00 5 2016-05-10 Rheumatoid arthritis
• RANDOMIZED STUDY COMPARING SENTINEL NODE POLICY TO CURRENT INITIAL STAGING PROTOCOLS IN EARLY STAGE ENDOMETRIAL CARCINOMAS AT INTERMEDIATE A … Ended recruitment
  2024-513079-42-00 5 2015-11-19 Intermediate-risk, high risk endometrial cancer
• A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas (REGOBONE) Ended recruitment
  2024-513455-33-00 4 2014-09-11 Bone sarcoma
• A large-scale comparative study evaluating an intravenous treatment, cabazitaxel, and radiation therapy to the pelvic lymph nodes in patient … Ended recruitment
  2024-517622-25-00 5 2013-12-06 Patients with localized prostate cancer and high-risk features of rela
• Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy. Ended recruitment
  2024-511142-39-00 5 2013-09-06 BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer
• A two-year, double-blind, randomized, multicenter, active controlled Core Phase study to evaluate the safety and efficacy of fingolimod admi … Ended recruitment
  2023-507556-68-00 5 2013-07-26 Multiple Sclerosis
• Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free … Ended recruitment
  2024-516198-61-00 5 2013-06-05 Patients with high risk of relapse, ER+ and HER2- primary non-metastat
• Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients Ended recruitment
  2024-515171-35-00 5 2011-07-06 Prostatic adenocarnicoma with high risk of recurrence
• A 24-week with possible extension, prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel group with a randomiza … Halted
  2024-514538-19-00 5 2025-11-26 Mastocytosis
• Salvage Therapy for Patients with Inadequate Response to Standard of Care Therapy in Granulomatosis with Polyangiitis Halted
  2024-516687-28-00 5 2025-06-06 Patients with GPA and inadequate response to standard of care therapy
• A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors with KRAS G12D Mutation Halted
  2023-507091-47-00 1 2025-02-10 Advanced or metastatic solid tumors
• A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-6404 … Halted
  2023-505096-68-00 4 2025-01-14 Preclinical Alzheimer’s Disease
• A 24-week, multicenter, randomized, double blind, placebo-controlled, dose-range finding phase II study to compare efficacy and safety of or … Halted
  2024-515193-27-00 4 2024-09-19 Mast cell activation syndrome
• VEN-R DASA-IPC 2022-067 Evaluation of DASATINIB monotherapy efficacy in acute myeloid leukemia patients refractory to VENETOCLAX-AZACITIDINE Halted
  2023-505846-24-00 4 2024-04-08 acute myeloid leukemia
• Induction chemotherapy followed by standard concurrent chemoradiotherapy in cervical cancer with para-aortic lymph node involvement: A phase … Halted
  2024-513576-18-00 5 2020-07-17 Cervical Cancer
• GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease. Ended
  2025-521107-42-00 4 2025-11-25 Alzheimer's Disease
• A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together with Either Pembrolizumab, Standard Therapies, or Both, in Adults with Solid T … Ended
  2023-505084-37-00 7 2025-03-17 Advanced Solid Tumors
• A Study of the Efficacy and Safety of Brensocatib in Adults with Moderate to Severe Hidradenitis Suppurativa Ended
  2024-515959-38-00 4 2025-03-06 Hidradenitis Suppurativa
• A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome Ended
  2023-507680-19-00 4 2024-11-28 Sjögren’s Syndrome
• Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHIN … Ended
  2023-508812-45-00 10 2024-11-11 Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures
• Multicenter randomized controlled trial of the value of intravitreal anti-VEGF injections as initial then adjuvant treatment in Coats' disea … Ended
  2024-517036-21-00 4 2024-11-06 Coats' disease
• A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy Ended
  2024-511998-30-00 5 2024-10-18 Narcolepsy with Cataplexy (Narcolepsy Type 1)

Showing 505–528 of 642 trials